Who
Christopher U. Missling
President and CEO
Company insider
Files Form 4 as: President and CEO, Anavex Life Sciences.
In numbers
- Trades disclosed
- 79
- Buys
- 39
- Sells
- 3
- Bought
- $60K
- Sold
- $3.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Apr 2015
- Last trade
- 6 Jan 2026
- Last filed
- 9 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Jan 2026filed 9 Jan 2026 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 6 Jan 2026filed 9 Jan 2026 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 2 Oct 2025filed 3 Oct 2025 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 11 Sep 2025filed 12 Sep 2025 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —187,500 at $0.00 | filing |
| 11 Sep 2025filed 12 Sep 2025 | AVXL Anavex Life SciencesBiotechnology | SEC FORM 4 Code M | $945K187,500 at $5.04 | filing |
| 11 Sep 2025filed 12 Sep 2025 | AVXL Anavex Life SciencesBiotechnology | SEC FORM 4 Code F | $1.4M145,048 at $9.58 | filing |
| 20 Aug 2025filed 22 Aug 2025 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 28 Apr 2025filed 30 Apr 2025 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 24 Mar 2025filed 26 Mar 2025 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —500,000 at $0.00 | filing |
| 24 Mar 2025filed 26 Mar 2025 | AVXL Anavex Life SciencesBiotechnology | SEC FORM 4 Code M | $460K500,000 at $0.92 | filing |
| 24 Mar 2025filed 26 Mar 2025 | AVXL Anavex Life SciencesBiotechnology | SEC FORM 4 Code F | $2.7M282,497 at $9.63 | filing |
| 15 Jan 2025filed 17 Jan 2025 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —166,666 at $0.00 | filing |
| 15 Jan 2025filed 17 Jan 2025 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 19 Dec 2024filed 23 Dec 2024 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 19 Nov 2024filed 6 Dec 2024 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 28 Mar 2024filed 1 Apr 2024 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —73,380 at $0.00 | filing |
| 28 Mar 2024filed 1 Apr 2024 | AVXL Anavex Life SciencesBiotechnology | SEC FORM 4 Code M | $97K73,380 at $1.32 | filing |
| 28 Mar 2024filed 1 Apr 2024 | AVXL Anavex Life SciencesBiotechnology | SEC FORM 4 Sold | $375K73,380 at $5.11 | filing |
| 2 Jan 2024filed 12 Jan 2024 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 29 Jun 2023filed 30 Jun 2023 | AVXL Anavex Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —232,000 at $0.00 | filing |
News
Kaplan Fox Encourages Anavex Life Sciences Corp. (NASDAQ: AVXL) Investors ...AVXL · pr-inside.com · 14 Oct 2026ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXLAVXL · wallstreet-online.de · 13 Oct 2026Kaplan Fox Encourages Investors of Anavex Life Sciences Corp. (NASDAQ:AVXL) ...AVXL · pr-inside.com · 9 Oct 2026
0 headlines in the last 90 days name Christopher U. Missling; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.